Grupo Espanol Multidisciplinario del Cancer Digestivo

2 in Phase 3

Quick facts

Phase 3 pipeline

5-Fluoruracil · Oncology
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.
total neoadjuvant therapy

Phase 2 pipeline

Anti-EGFR or Bevacizumab · Oncology
Inhibits vascular endothelial growth factor A (VEGFA)
Atezolizumab plus Tiraglolumab · Oncology
Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.
bevacizumab, capecitabine, oxaliplatin
Capecitabine during all Radiotherapy period · Oncology
Capecitabine is a thymidylate synthase inhibitor.
Chemotherapy plus monoclonal antibody · Oncology
Chemotherapy plus monoclonal antibody works by targeting cancer cells with a combination of chemotherapy agents and monoclonal antibodies that specifically bind to and destroy cancer cells.
Gemcitabine and Erlotinib · Oncology
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
LIVERPEARLS-Irinotecan
panitumumab, mytomicin C, 5-FU, radiation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Grupo Espanol Multidisciplinario del Cancer Digestivo

What is Grupo Espanol Multidisciplinario del Cancer Digestivo's pipeline?

Grupo Espanol Multidisciplinario del Cancer Digestivo has 2 drugs in Phase 3, 8 in Phase 2, 0 in Phase 1. Late-stage candidates include 5-Fluoruracil, total neoadjuvant therapy.

Sector hub: All tracked pharma companies